Cargando…
Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study
BACKGROUND & AIMS: We aimed to assess the safety and immunogenicity of inactivated whole-virion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic liver diseases (CLD) in this study. METHODS: This was a prospective, multi-center, open-label study. Part...
Ejemplares similares
-
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study
por: Wang, Jitao, et al.
Publicado: (2021) -
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study
por: Wang, Jitao, et al.
Publicado: (2022) -
Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
por: Zhao, Xiang, et al.
Publicado: (2023) -
Gallbladder neuroendocrine carcinoma: A report of two cases and literature review
por: Liao, Yong, et al.
Publicado: (2023) -
Gaps in studies of global health education: an empirical literature review
por: Liu, Yan, et al.
Publicado: (2015)